Protara Therapeutics (TARA) Non-Current Deferred Tax Liability (2019 - 2023)

Protara Therapeutics (TARA) has reported Non-Current Deferred Tax Liability for 5 consecutive years, with $9.6 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Non-Current Deferred Tax Liability rose 43786.36% year-over-year to $9.6 million; the TTM figure through Dec 2023 stood at $9.6 million (up 43786.36% YoY), while the FY2023 annual figure was $9.6 million, up 43786.36% from the prior year.
• Non-Current Deferred Tax Liability rose to $9.6 million in Q4 2023 per TARA's latest filing, from -$22000.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $9.6 million in Q4 2023 and bottomed at -$22000.0 in Q4 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $1.6 million across 5 years, with a median of $355500.0 in 2020.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability plunged 101.42% — and 2023, when it surged 43786.36%.
• Protara Therapeutics' Non-Current Deferred Tax Liability stood at $2000.0 in 2019, then soared by 16000.0% to $322000.0 in 2020, then soared by 381.06% to $1.5 million in 2021, then slumped by 101.42% to -$22000.0 in 2022, then soared by 43786.36% to $9.6 million in 2023.
• Business Quant data shows TARA's Non-Current Deferred Tax Liability at $9.6 million in Q4 2023, -$22000.0 in Q4 2022, and $829000.0 in Q3 2022.